Specific to cardiovascular-related death, ELIXA and SUSTAIN-6 trials showed similar performance relative to the placebo [ HR = 0.98 (95% CI 0.781.22) and HR = 0.98 (95% CI 0.651.48), respectively]
The net cardiac benefit of weight loss typically outweighs arrhythmia risk for most patients, but individualized assessment is essential
What Youll Learn: What GLP-1s (Ozempic, Wegovy, Mounjaro, etc.) are, how they work, and what the current evidence shows The potential benefits and risks - medical, psychological, and social Questions of access, equity, stigma, and the cultural narratives surrounding weight What we know (and dont yet know) about the long-term outlook and what comes after GLP-1s How to make or support informed, autonomous decisions about treatment options Whats Included in This Digital Bundle: 2.5-hours video recording presentation slides Printable note-taking materials Private access to a dedicated course page Lifetime access return anytime, learn at your own pace Certificate of Attendance (issued after feedback form submission) Who Its For: This course is designed for anyone interested in understanding GLP-1s from individuals thinking about starting the journey, to those supporting loved ones, to professionals in health and wellbeing fields
Columbus Instruments, USA)
Prior pancreatitis, gallbladder disease, kidney problems, diabetic retinopathy, significant gastrointestinal symptoms, and use of insulin or sulfonylureas may require closer risk assessment rather than automatic exclusion
